| scholarly article | Q13442814 |
| P2093 | author name string | Zhongyang Shen | |
| Qingjun Guo | |||
| Wentao Jiang | |||
| Jisan Sun | |||
| Dazhi Tian | |||
| P2860 | cites work | Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. | Q52583955 |
| Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. | Q52639687 | ||
| Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. | Q53630404 | ||
| Icotinib enhances lung cancer cell radiosensitivity in vitro and in vivo by inhibiting MAPK/ERK and AKT activation. | Q54109233 | ||
| Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. | Q54339119 | ||
| Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience | Q83809945 | ||
| Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type | Q88982783 | ||
| Hepatocellular carcinoma: a review | Q28069290 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma | Q33863710 | ||
| Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies | Q34082260 | ||
| The Cellular Apoptosis Susceptibility Protein (CAS) Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis and Cell Proliferation | Q36518331 | ||
| Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma | Q37650062 | ||
| Targeting the ERBB family in cancer: couples therapy | Q38129286 | ||
| Advances in targeted therapies for hepatocellular carcinoma in the genomic era. | Q38521011 | ||
| The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib | Q38770483 | ||
| EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. | Q38872276 | ||
| Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation | Q38912283 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. | Q39996225 | ||
| Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. | Q40463024 | ||
| Analysis of liver cancer incidence and trend in China | Q40949376 | ||
| Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis | Q45231150 | ||
| EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. | Q49958316 | ||
| PD-L1 expression according to the EGFR status in primary lung adenocarcinoma | Q50139973 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 8227-8237 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression | |
| P478 | volume | 11 |
| Q100490607 | Advances in targeted therapy for esophageal cancer |
| Q89624059 | Recent advances in liver transplantation for cancer: The future of transplant oncology |
Search more.